TriNetX’s Treatment Pathways analytic simplifies the analysis of real-world data (RWD) of patient treatment pathways geographically and chronologically.
Alex Eastmen, VP, Product Management at TriNetX, said in a statement, “Studying treatment pathways has always involved resource intensive physician interviews, laborious literature review, difficult analysis of longitudinal data, and writing custom code to visualize data.”
He further explained that with the analytic platform offered by the research network, researchers can get the analysis they need “in minutes with just a few mouse clicks” and the data of over 16 countries, representing 300 million patients, is continuously refreshed.
TriNetX Research, an additional self-service offering works directly with the Treatment Pathways analytic offering. The research platform uses the networks longitudinal clinical and genomic data to develop analytics, from which real-world data can be searched through the Treatment Pathways offering. The organization’s network includes real-time access to de-identified RWD to bolster its analytic capabilities.
Becca Fink, director of Product Management at TriNetX Research, added that the platform gives users the ability to custom analyses for specific indications.
Bolstering the analytical capabilities, TriNetX’s cloud-based platform, TNX, has on-demand access to longitudinal clinical, genomic, and claims data. From this source, researchers can explore and compare cohort characteristics prior to an event and compare outcomes after.
The TriNetX platform has partnerships with pharmaceutical and health care companies like Sanofi, Pfizer, Tufts, and Allergen.
